© 2024. 代谢相关脂肪性肝病临床科研与疾病管理大数据共享平台
| 论文标题 | 作者 | 发表时间 | 发表杂志 | 影响因子 |
|---|---|---|---|---|
| Predictors of Fibrosis, Clinical Events and Mortality in MASLD: Data from the GlobalMASLD Study | Younossi ZM, de Avila L, Petta S, Hagström H, Kim SU, Nakajima A, Crespo J, Castera L, Alkhouri N, Zheng MH, Treeprasertsuk S, Ananchuensook P, Shalimar, Tsochatzis E, Trivikrama SK, Balakumaran LK, Fan JG, Roberts SK, Alswat K, Wong VW, Yilmaz Y, Dunn W, Francque S, Cordie A, Yu ML, Ekstedt M, Goh GB, Oliveira CP, Pessoa MG, Chan WK, Fernandez MIC, Duseja A, Arab JP, Papatheodoridis G, Sebastiani G, Villela-Nogueira C, D'Ambrosio R, Lampertico P, Alnaamani K, Holleboom AG, Valsan A, Venu A, El-Kassas M, Pennisi G, Shang Y, Liu WY, Lee HW, Kobayashi T, Kakizaki S, Caussy C, Pearlman B, Iruzubieta P, Nadeem R, Cinque F, Neonaki A, Zoncapé M, Yang RX, Song SJ, Dunn N, Gadi Z, Yeh ML, The KK, Mahadeva S, Fabian LG, Almohsen A, Leite N, Pugliese N, Vessby J, Xie C, Choudhary NS, Friend E, Poca M, Kawaguchi T, Russo FP, Gadano A, Diaz LA, Singal AK, Segrestin B, Gunn N, Mauricio D, Arrese M, Fracanzani A, Lam B, Racila A, Alqahtani SA, Stepanova M |
2025-11 |
Hepatology (Baltimore, Md.) |
15.8 |
| Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study | Jeffrey V Lazarus ，Leire Agirre-Garrido ，Trenton M White ，Anish K Arora ，Melina I Manolas ，Luis Antonio Diaz ，Juan Pablo Arab ，Shira Zelber-Sagi ，Naim Alkhouri ，C Wendy Spearman，Jörn M Schattenberg，Loreta A Kondili，Patrizia Carrieri，Holly F Lofton，Priya Jaisinghani，Sonal Kumar，Ajay Duseja，Mohamed El-Kassas，Hirokazu Takahasi，Debbie L Shawcross，Jonathan G Stine，Marcela Villota-Rivas，Juan Emilio Miralles-Sanchez，Silvana Pannain，Paul N Brennan，MASLD/MASH Collaborators |
2025-12 |
The lancet. Gastroenterology & hepatology |
38.6 |
| Hepatic Insulin Resistance and Steatosis in Metabolic DysfunctionAssociated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications | Xuan Trong Truong ， Dae Ho Lee |
2025-09 |
Diabetes & metabolism journal |
8.5 |
| Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis | Wenhao Li , William Alazawi , Rohit Loomba |
2025-11 |
The lancet. Gastroenterology & hepatology |
38.6 |
| Weight loss in MASLD restores the balance of liver fatty acid sources | Jennifer E Lambert , Maria A Ramos-Roman , Maressa J Valdez , Jeffrey D Browning , Thomas Rogers , Elizabeth J Parks |
2025-05 |
The Journal of clinical investigation |
13.6 |
| Association of weight-adjusted waist index with all-cause and cardiovascular mortality in patients with metabolic dysfunctionassociated steatotic liver disease: a national population-based cohort study | Fan Zhang , Yan Han , Yonghua Mao , Wenjian Li |
2025-09 |
BMC cardiovascular disorders |
2.3 |
| Relationship between MASLD and women’s health: A review | Pavlina Jancova , Khaled Ismail， Lucie Vistejnova |
2025-10 |
Women's health (London, England) |
2.9 |
| MASLD development: From molecular pathogenesis toward therapeutic Strategies | Zhu Yang , Jiahui Zhao, Kexin Xie1, Chengwei Tang, Can Gan, Jinhang Gao |
2025-07 |
Chinese medical journal |
7.3 |
| The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD | The Zou H, Xie J, Ma X, Xie Y. |
2025-03 |
Can J Gastroenterol Hepatol |
2.3 |
| Bariatric surgery for metabolic dysfunction–associated steatotic liver disease (MASLD): Current knowledge of mechanisms | Liu Hanyang,Lefere Sander, Guillot Adrien, Zheng Ming-Hua, Tacke Frank |
2025-05 |
Hepatology |
12.9 |
